India rejects plea against cancer drug – Boston Globe
![]() Boston Globe |
India rejects plea against cancer drug
Boston Globe Last year, India’s patent office allowed local drug manufacturer Natco Pharma Ltd. to produce a generic version of Bayer’s kidney and liver cancer drug Nexavar on the grounds it would make the drug available to the public at a reasonably affordable price. Enter compulsory licensingBusiness Standard Indian patent appeal board upholds compulsory license on Bayer’s NexavarThe Pharma Letter IPAB rejects Bayer’s appeal on the grant of Compulsory LicenseLexology (registration) Morning Star Online –Newstalk ZB all 52 news articles » |


